Moderna, Inc. (MRNA)
Short Squeeze Alert—Moderna Stock Surges on New Strategy
At that time, Moderna revealed its strategy for using mRNA to combat cancer and rare diseases. It's a move beyond vaccines, and investors seem to like it.
MRNA Stock Jumps to 52-Week High on Expansion Plans Beyond Vaccines
Moderna hit a 52-week high after it unveiled a strategy to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases and AI-driven R&D.
Moderna stock soars as cancer pipeline and CAR-T push ignite optimism
Moderna Inc. (MRNA) shares surged nearly 10% on Friday, extending a powerful rally that has lifted the stock about 40% over the past month and significantly outperformed the broader market. The gains followed the company's Science Day presentation and investor event, where Moderna outlined an ambitious strategy to expand beyond its COVID-19 vaccine business and build a diversified portfolio spanning oncology, autoimmune diseases, and next-generation mRNA therapies.
Moderna Is Up 13% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer?
Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up 14% to $68 and change in afternoon trading Friday, extending a remarkable run for the mRNA pioneer.
Why Moderna Stock Is Soaring and Leading the S&P 500 Today
Moderna shares pace toward their highest close since late 2024 after unveiling a new cell therapy program.
Moderna, Inc. (MRNA) Discusses Advancements in mRNA Technology, Clinical Modalities, and Future Horizons in Science Transcript
Moderna, Inc. (MRNA) Discusses Advancements in mRNA Technology, Clinical Modalities, and Future Horizons in Science Transcript
Moderna (MRNA) Rises As Market Takes a Dip: Key Facts
Moderna (MRNA) closed at $61 in the latest trading session, marking a +2.79% move from the prior day.
MRNA Up as Influenza Vaccine Wins Unanimous FDA Advisory Panel Backing
Moderna stock gains 3.5% after FDA advisory panel votes 9-0 that mFlusiva's benefits outweigh risks in influenza prevention in older adults, ahead of an Aug. 5 decision.
FDA Votes in Favor of Benefit-Risk Profile for Moderna's Flu Vaccine
Moderna said the FDA's Vaccines and Related Biological Products Advisory Committee voted unanimously that the benefits of the vaccine, mRNA-1010, exceed the risks for the prevention of flu in adults 50 through 64 years old, and in adults 65 years of age and older.
US FDA advisers vote in favor of Moderna's flu vaccine
The U.S. Food and Drug Administration's advisers on Thursday backed approval of Moderna's flu vaccine in adults aged 50 and older, saying its benefits outweigh the risks.
MRNA Stock Jumps as FDA Briefing Docs Ease Flu Shot Approval Concerns
Moderna jumps after FDA briefing documents on mFlusiva appear more constructive than expected ahead of a key advisory panel review.
Moderna (MRNA) Surges 6.3%: Is This an Indication of Further Gains?
Moderna (MRNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
